Pharmaceutical care of a patient with inflammatory bowel disease and atrial fibrillation
10.12206/j.issn.2097-2024.202403004
- VernacularTitle:1例炎症性肠病合并心房颤动患者的用药分析与监护
- Author:
Jinfa CAO
1
;
Ling ZHONG
2
;
Miao HE
3
;
Jing TIAN
3
Author Information
1. Department of Pharmacy, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China;Department of Pharmacy, Taikang Tongji （Wuhan） Hospital, Wuhan 430050, China.
2. Department of Pharmacy, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China;Department of Pharmacy, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China.
3. Department of Pharmacy, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
- Publication Type:Medicine&Clinical
- Keywords:
Inflammatory bowel disease;
atrial fibrillation;
peptic ulcer;
antithrombotic therapy;
pharmaceutical care
- From:
Journal of Pharmaceutical Practice and Service
2025;43(10):525-528
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the disease characteristics, potential drug interactions, and key points of pharmaceutical care in patients with inflammatory bowel disease and atrial fibrillation, so as to provide a reference for rational clinical medication use. Methods Through involvement in the pharmaceutical care of a patient with inflammatory bowel disease and atrial fibrillation, and by reviewing relevant literature, the clinical pharmacist assessed the rationality of the medication regimen, proposed medication reconciliation recommendations, and assisted the multidisciplinary team in optimizing the treatment plan. Results Following the intervention, the patient's inflammatory bowel disease-related symptoms were improved significantly, atrial fibrillation was effectively controlled, and no significant adverse drug reactions were observed. Conclusion There exists a complex bidirectional interaction between inflammatory bowel disease and atrial fibrillation in terms of pathological mechanisms and pharmacotherapy. Through individualized medication reconciliation and multidisciplinary pharmaceutical care, safe and effective long-term management of those patients can be achieved.
